RPV LA + CAB LA for HIV Prevention in Healthy Participants

"Patients suffering from HIV-1, who have never been on antiretroviral therapy and weigh at least 35 kg, may be eligible for RPV LA treatment."

"This medical trial only allows applicants within the 18-55 age range. In contrast, there are 55 studies for minors and 383 investigations with elderly participants."

"The principal purpose of this trial, lasting up to 72 weeks, is to ascertain the plasma concentration of cabotegravir. Secondary aims include ascertaining how many patients experience an injection-site reaction and evaluating pain intensity through visual analogue scale (VAS). The study will also collect information on any abnormalities in 12-lead electrocardiograms (ECGs) such as heart rate, PR interval, QRS duration and corrected QT interval (QTc)."

"As per clinicaltrials.gov, this trial is actively searching for volunteers to participate in the study. The initial open call was announced on November 16th 2021 and updated recently on November 22nd 2022."

"This clinical trial is recruiting 135 participants, aged 18 to 55 years old. In order for a potential patient to be eligible, they must pass certain tests and meet the following criteria: women may not donate eggs or freeze them for assisted reproduction during this study; physical examination, medical history check-up, vital signs monitoring and 12-lead electrocardiogram (ECG) must indicate good health; laboratory results should also reflect healthiness; all female participants need to receive negative highly sensitive serum Beta hCG pregnancy test prior to dosing on Day 1; sexually active male candidates without vasectomy are required to use two reliable contraceptive methods throughout the"

"RPV LA was initially examined at University of Zurich in 2002, accumulating a total of 55 completed clinical trials. In the present day, 15 live tests are being conducted with numerous sites located in Salt Lake City, Utah."

"Affirmative. The information on clinicaltrials.gov displays that this research, which was published on November 16th 2021, is actively enrolling participants. Currently 135 volunteers are needed to be enrolled from two distinct medical facilities."

"Our internal assessment at Power has placed RPV LA's safety on a scale of 1, which is the lowest category. This reflects that this Phase 1 trial only holds limited evidence to support its efficacy and security."